Additionally, the 36-month beta value for PACB is 1.96. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for PACB is 262.20M and currently, short sellers hold a 19.22% ratio of that float. The average trading volume of PACB on November 18, 2024 was 8.95M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PACB) stock’s latest price update
Pacific Biosciences of California Inc (NASDAQ: PACB)’s stock price has decreased by -14.02 compared to its previous closing price of 1.86. However, the company has seen a -30.65% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-12 that Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term growth given the rapid technological advancements in the genomic market.
PACB’s Market Performance
PACB’s stock has fallen by -30.65% in the past week, with a monthly drop of -16.05% and a quarterly drop of -0.31%. The volatility ratio for the week is 16.31% while the volatility levels for the last 30 days are 13.22% for Pacific Biosciences of California Inc The simple moving average for the last 20 days is -24.24% for PACB stock, with a simple moving average of -35.48% for the last 200 days.
Analysts’ Opinion of PACB
Jefferies, on the other hand, stated in their research note that they expect to see PACB reach a price target of $4. The rating they have provided for PACB stocks is “Buy” according to the report published on June 03rd, 2024.
PACB Trading at -16.74% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.02% of loss for the given period.
Volatility was left at 13.22%, however, over the last 30 days, the volatility rate increased by 16.31%, as shares sank -19.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.95% upper at present.
During the last 5 trading sessions, PACB fell by -30.65%, which changed the moving average for the period of 200-days by -76.41% in comparison to the 20-day moving average, which settled at $2.1053. In addition, Pacific Biosciences of California Inc saw -83.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Kim Susan G., who sale 19,782 shares at the price of $1.72 back on Sep 30 ’24. After this action, Kim Susan G. now owns 695,654 shares of Pacific Biosciences of California Inc, valued at $34,065 using the latest closing price.
SUSAN KIM, the Officer of Pacific Biosciences of California Inc, proposed sale 19,782 shares at $1.72 during a trade that took place back on Sep 30 ’24, which means that SUSAN KIM is holding shares at $34,061 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -2.15 for the present operating margin
- 0.18 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -2.28. The total capital return value is set at -0.27. Equity return is now at value -64.80, with -23.55 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 2.01. The interest coverage ratio of the stock is -26.21.
Currently, EBITDA for the company is -277.28 million with net debt to EBITDA at -2.49. When we switch over and look at the enterprise to sales, we see a ratio of 7.39. The receivables turnover for the company is 5.89for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.74.
Conclusion
In conclusion, Pacific Biosciences of California Inc (PACB) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
